candoxatrilat has been researched along with arginine vasopressin in 1 studies
| Studies (candoxatrilat) | Trials (candoxatrilat) | Recent Studies (post-2010) (candoxatrilat) | Studies (arginine vasopressin) | Trials (arginine vasopressin) | Recent Studies (post-2010) (arginine vasopressin) |
|---|---|---|---|---|---|
| 46 | 10 | 1 | 12,278 | 422 | 1,212 |
| Protein | Taxonomy | candoxatrilat (IC50) | arginine vasopressin (IC50) |
|---|---|---|---|
| Vasopressin V2 receptor | Homo sapiens (human) | 0.242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aragno, M; Danni, O; Mastrocola, R; Mengozzi, G; Parola, M; Restivo, F; Rizzetto, M; Rosina, F; Sansoè, G; Smedile, A | 1 |
1 other study(ies) available for candoxatrilat and arginine vasopressin
| Article | Year |
|---|---|
Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?
Topics: Animals; Arginine Vasopressin; Atrial Natriuretic Factor; Blood Pressure; Carbon Tetrachloride; Cyclic GMP; Cyclohexanecarboxylic Acids; Cytokines; Endothelin-1; Humans; Hypertension, Portal; Liver; Liver Cirrhosis, Experimental; Male; Neprilysin; Portal Vein; Protease Inhibitors; Rats; Rats, Wistar; Vascular Resistance | 2005 |